Go to Home

Search

-Advanced Search   -Search Guidelines

Ann Pediatr Endocrinol Metab.  2023 Sep;28(3):168-177. 10.6065/apem.2346168.084.

2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents

Affiliations
  • 1Department of Pediatrics, Inha University Hospital, Inha University College of Medicine, Incheon, Korea
  • 2Department of Pediatrics, Dongguk University Ilsan Hospital, Goyang, Korea
  • 3Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University School of Medicine, Bucheon, Korea
  • 4Department of Pediatrics, National Health Insurance Service Ilsan Hospital, Goyang, Korea
  • 5Department of Pediatrics, Catholic Kwandong University International St. Mary’s Hospital, Incheon, Korea
  • 6Department of Pediatrics, Korea University College of Medicine, Seoul, Korea
  • 7Department of Pediatrics, Hanyang University Medical Center, Hanyang University College of Medicine, Seoul, Korea
  • 8Department of Pediatrics, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
  • 9Department of Pediatrics, CHA Bundang Medical Center, CHA University, Seongnam, Korea
  • 10Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
  • 11Department of Family Medicine, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea

Abstract

The Committee of Central Precocious Puberty of Korean Pediatrics and Adolescents of the Korean Society of Pediatric Endocrinology has newly developed evidence-based 2022 clinical practice guidelines for central precocious puberty in Korean children and adolescents. These guidelines provide the grade of recommendations, which includes both the strength of recommendations and the level of evidence. In the absence of sufficient evidence, recommendations are based on expert opinion. These guidelines have been revised and supplement the previous guidelines "Clinical Guidelines for Precocious Puberty 2011," and are drawn from a comprehensive review of the latest domestic and international research and the grade of recommendation appropriate to the domestic situation. This review summarizes the newly revised guidelines into 8 key questions and 27 recommendations and consists of 4 sections: screening, diagnosis, treatment, and long-term outcome of central precocious puberty.

Keyword

Precocious puberty; Central precocious puberty; Practice guideline; Child; Adolescent; Korea

Reference

References

1. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969; 44:291–303.
2. Kim SH, Huh K, Won S, Lee KW, Park MJ. A significant increase in the incidence of central precocious puberty among Korean girls from 2004 to 2010. PLoS One. 2015; 10:e0141844.
3. Kim YJ, Kwon A, Jung MK, Kim KE, Suh J, Chae HW, et al. Incidence and prevalence of central precocious puberty in Korea: an epidemiologic study based on a national database. J Pediatr. 2019; 208:221–8.
4. 2011 Clinical Practice Guideline for Korean Children and Adolescents Seoul (Korea): Korean Society of Pediatric Endocrinology, 2011.
5. McCartney CR, Blank SK, Prendergast KA, Chhabra S, Eagleson CA, Helm KD, et al. Obesity and sex steroid changes across puberty: evidence for marked hyperandrogenemia in pre- and early pubertal obese girls. J Clin Endocrinol Metab. 2007; 92:430–6.
6. Li W, Liu Q, Deng X, Chen Y, Liu S, Story M. Association between obesity and puberty timing: a systematic review and meta-analysis. Int J Environ Res Public Health. 2017; 14:1266.
7. Brix N, Ernst A, Lauridsen LLB, Parner ET, Arah OA, Olsen J, et al. Childhood overweight and obesity and timing of puberty in boys and girls: cohort and sibling-matched analyses. Int J Epidemiol. 2020; 49:834–44.
8. de Groot CJ, van den Berg A, Ballieux B, Kroon HM, Rings E, Wit JM, et al. Determinants of advanced bone age in childhood obesity. Horm Res Paediatr. 2017; 87:254–63.
9. Deng X, Li W, Luo Y, Liu S, Wen Y, Liu Q. Association between small fetuses and puberty timing: a systematic review and meta-analysis. Int J Environ Res Public Health. 2017; 14:1377.
10. Darendeliler F. IUGR: Genetic influences, metabolic problems, environmental associations/triggers, current and future management. Best Pract Res Clin Endocrinol Metab. 2019; 33:101260.
11. Verkauskiene R, Petraitiene I, Albertsson Wikland K. Puberty in children born small for gestational age. Horm Res Paediatr. 2013; 80:69–77.
12. Suikkanen J, Nurhonen M, Cole TJ, Paalanne M, Matinolli HM, Tikanmaki M, et al. Preterm birth and subsequent timing of pubertal growth, menarche, and voice break. Pediatr Res. 2022; 92:199–205.
13. Shim YS, Lee HS, Hwang JS. Genetic factors in precocious puberty. Clin Exp Pediatr. 2022; 65:172–81.
14. Wohlfahrt-Veje C, Mouritsen A, Hagen CP, Tinggaard J, Mieritz MG, Boas M, et al. Pubertal onset in boys and girls is influenced by pubertal timing of both parents. J Clin Endocrinol Metab. 2016; 101:2667–74.
15. Li W, Liu Q, Deng X, Chen Y, Liu S, Story M. Association between obesity and puberty timing: a systematic review and meta-analysis. Int J Environ Res Public Health. 2017; 14:1266.
16. Xu YQ, Li GM, Li Y. Advanced bone age as an indicator facilitates the diagnosis of precocious puberty. J Pediatr (Rio J). 2018; 94:69–75.
17. Freire AV, Escobar ME, Gryngarten MG, Arcari AJ, Ballerini MG, Bergada I, et al. High diagnostic accuracy of subcutaneous Triptorelin test compared with GnRH test for diagnosing central precocious puberty in girls. Clin Endocrinol (Oxf). 2013; 78:398–404.
18. Lee HY, Lee YJ, Ahn MB, Cho WK, Suh BK. The effect of overweight on the luteinizing hormone level after gonadorelin stimulation test in girls with idiopathic central precocious puberty. Ann Pediatr Endocrinol Metab. 2018; 23:215–9.
19. Neely EK, Wilson DM, Lee PA, Stene M, Hintz RL. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr. 1995; 127:47–52.
20. Houk CP, Kunselman AR, Lee PA. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls. Pediatrics. 2009; 123:e1059–63.
21. Lee HS, Park HK, Ko JH, Kim YJ, Hwang JS. Utility of Basal luteinizing hormone levels for detecting central precocious puberty in girls. Horm Metab Res. 2012; 44:851–4.
22. Kang YS, Yoo DY, Chung IH, Yoo EG. Diurnal variation of gonadotropin levels in girls with early stages of puberty. Ann Pediatr Endocrinol Metab. 2017; 22:183–8.
23. Lee DM, Chung IH. Morning basal luteinizing hormone, a good screening tool for diagnosing central precocious puberty. Ann Pediatr Endocrinol Metab. 2019; 24:27–33.
24. Sathasivam A, Rosenberg HK, Shapiro S, Wang H, Rapaport R. Pelvic ultrasonography in the evaluation of central precocious puberty: comparison with leuprolide stimulation test. J Pediatr. 2011; 159:490–5.
25. Wen X, Wen D, Zhang H, Zhang H, Yang Y. Observational study pelvic ultrasound a useful tool in the diagnosis and differentiation of precocious puberty in Chinese girls. Medicine (Baltimore). 2018; 97:e0092.
26. Nguyen NN, Huynh LBP, Do MD, Yang TY, Tsai MC, Chen YC. Diagnostic accuracy of female pelvic ultrasonography in differentiating precocious puberty from premature thelarche: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021; 12:735875.
27. Cantas-Orsdemir S, Garb JL, Allen HF. Prevalence of cranial MRI findings in girls with central precocious puberty: a systematic review and meta-analysis. J Pediatr Endocrinol Metab. 2018; 31:701–10.
28. Yoon JS, So CH, Lee HS, Lim JS, Hwang JS. Prevalence of pathological brain lesions in girls with central precocious puberty: possible overestimation? J Korean Med Sci. 2018; 33:e329.
29. Alikasifoglu A, Vuralli D, Gonc EN, Ozon A, Kandemir N. Changing etiological trends in male precocious puberty: evaluation of 100 cases with central precocious puberty over the last decade. Horm Res Paediatr. 2015; 83:340–4.
30. Yoon JS, So CH, Lee HS, Lim JS, Hwang JS. The prevalence of brain abnormalities in boys with central precocious puberty may be overestimated. PLoS One. 2018; 13:e0195209.
31. Zhu SY, Du ML, Huang TT. An analysis of predictive factors for the conversion from premature thelarche into complete central precocious puberty. J Pediatr Endocrinol Metab. 2008; 21:533–8.
32. Kaplowitz PB, Backeljauw PF, Allen DB. Toward more targeted and cost-effective gonadotropin-releasing hormone analog treatment in girls with central precocious puberty. Horm Res Paediatr. 2018; 90:1–7.
33. Massart F, Federico G, Harrell JC, Saggese G. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty. Neuroendocrinology. 2009; 90:307–14.
34. Franzini IA, Yamamoto FM, Bolfi F, Antonini SR, Nunes-Nogueira VS. GnRH analog is ineffective in increasing adult height in girls with puberty onset after 7 years of age: a systematic review and meta-analysis. Eur J Endocrinol. 2018; 179:381–90.
35. Bertelloni S, Massart F, Miccoli M, Baroncelli GI. Adult height after spontaneous pubertal growth or GnRH analog treatment in girls with early puberty: a meta-analysis. Eur J Pediatr. 2017; 176:697–704.
36. Magiakou MA, Manousaki D, Papadaki M, Hadjidakis D, Levidou G, Vakaki M, et al. The efficacy and safety of gonadotropin-releasing hormone analog treatment in childhood and adolescence: a single center, long-term follow-up study. J Clin Endocrinol Metab. 2010; 95:109–17.
37. Guaraldi F, Beccuti G, Gori D, Ghizzoni L. Management of endocrine disease: long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol. 2016; 174:R79–87.
38. Bangalore Krishna K, Fuqua JS, Rogol AD, Klein KO, Popovic J, Houk CP, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr. 2019; 91:357–72.
39. Calcaterra V, Klersy C, Vinci F, Regalbuto C, Dobbiani G, Montalbano C, et al. Rapid progressive central precocious puberty: diagnostic and predictive value of basal sex hormone levels and pelvic ultrasound. J Pediatr Endocrinol Metab. 2020; 33:785–91.
40. Park HK, Choo MS, Shim YS. Adult height after gonadotropin-releasing hormone agonist treatment in girls with early puberty: a meta-analysis. Clin Endocrinol (Oxf). 2020; 93:135–45.
41. Bertelloni S, Mul D. Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl. 2008; 10:525–34.
42. Kaplowitz PB. Treatment of central precocious puberty. Curr Opin Endocrinol Diabetes Obes. 2009; 16:31–6.
43. Menk TAS, Inacio M, Macedo DB, Bessa DS, Latronico AC, Mendonca BB, et al. Assessment of stress levels in girls with central precocious puberty before and during long-acting gonadotropin-releasing hormone agonist treatment: a pilot study. J Pediatr Endocrinol Metab. 2017; 30:657–62.
44. Copeland W, Shanahan L, Miller S, Costello EJ, Angold A, Maughan B. Outcomes of early pubertal timing in young women: a prospective population-based study. Am J Psychiatry. 2010; 167:1218–25.
45. Wojniusz S, Callens N, Sutterlin S, Andersson S, De Schepper J, Gies I, et al. Cognitive, emotional, and psychosocial functioning of girls treated with pharmacological puberty blockage for idiopathic central precocious puberty. Front Psychol. 2016; 7:1053.
46. Chung LY, Kang E, Nam HK, Rhie YJ, Lee KH. Efficacy of triptorelin 3-month depot compared to 1-month depot for the treatment of Korean girls with central precocious puberty in single tertiary center. J Korean Med Sci. 2021; 36:e219.
47. Jeon MJ, Choe JW, Chung HR, Kim JH. Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2021; 26:171–7.
48. Torres-Tamayo M, Zurita-Cruz JN, Aguilar-Herrera BE, Miranda-Lora AL, Calzada-Leon R, Rivera-Hernandez AJ, et al. Adjuvant interventions in the treatment of precocious puberty: clinical guideline for the diagnosis and treatment of precocious puberty. Bol Med Hosp Infant Mex. 2020; 77(Supl 1):26–8.
49. Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR; ESPE-LWPES GnRH Analogs Consensus Conference Group, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009; 123:e752–62.
50. Lee JW, Kim HJ, Choe YM, Kang HS, Kim SK, Jun YH, et al. Significant adverse reactions to long-acting gonadotropinreleasing hormone agonists for the treatment of central precocious puberty and early onset puberty. Ann Pediatr Endocrinol Metab. 2014; 19:135–40.
51. Yeshaya A, Kauschansky A, Orvieto R, Varsano I, Nussinovitch M, Ben-Rafael Z. Prolonged vaginal bleeding during central precocious puberty therapy with a long-acting gonadotropin-releasing hormone agonist. Acta Obstet Gynecol Scand. 1998; 77:327–9.
52. Inman M, Hursh BE, Mokashi A, Pinto T, Metzger DL, Cummings EA. Occurrence of slipped capital femoral epiphysis in children undergoing gonadotropin-releasing hormone agonist therapy for the treatment of central precocious puberty. Horm Res Paediatr. 2013; 80:64–8.
53. De Sanctis V, Soliman AT, Di Maio S, Soliman N, Elsedfy H. Long-term effects and significant Adverse Drug Reactions (ADRs) associated with the use of Gonadotropin-Releasing Hormone analogs (GnRHa) for central precocious puberty: a brief review of literature. Acta Biomed. 2019; 90:345–59.
54. Gul U, Kacar Bayram A, Kendirci M, Hatipoglu N, Okdemir D, Gumus H, et al. Pseudotumour cerebri presentation in a child under the gonadotropin-releasing hormone agonist treatment. J Clin Res Pediatr Endocrinol. 2016; 8:365–7.
55. Omar AA, Nyaga G, Mungai LNW. Pseudotumor cerebri in patient on leuprolide acetate for central precocious puberty. Int J Pediatr Endocrinol. 2020; 2020:22.
56. Luchinger AB, Mijatovic V, Rustemeyer T, Hompes PG. Anaphylactic reaction to different gonadotropin-releasing hormone agonists for the treatment of endometriosis. Am J Med Sci. 2011; 341:240–2.
57. Gu Q, Luo Y, Ye J, Shen X. Comparative efficacy and safety of three current clinical treatments for girls with central precocious puberty: a network meta-analysis. Endocr Pract. 2019; 25:717–28.
58. Kim MS, Koh HJ, Lee GY, Kang DH, Kim SY. Comparing adult height gain and menarcheal age between girls with central precocious puberty treated with gonadotropinreleasing hormone agonist alone and those treated with combined growth hormone therapy. Ann Pediatr Endocrinol Metab. 2019; 24:116–23.
59. Klein KO, Dragnic S, Soliman AM, Bacher P. Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate. J Pediatr Endocrinol Metab. 2018; 31:655–63.
60. Zurita-Cruz JN, Torres-Tamayo M, Aguilar-Herrera BE, Miranda-Lora AL, Rivera-Hernandez AJ, Calzada-Leon R, et al. Monitoring during the treatment of precocious puberty: clinical guideline for the diagnosis and treatment of precocious puberty. Bol Med Hosp Infant Mex. 2020; 77(Supl 1):29–34.
61. Lazar L, Phillip M. Pubertal disorders and bone maturation. Endocrinol Metab Clin North Am. 2012; 41:805–25.
62. Brito VN, Latronico AC, Arnhold IJ, Mendonca BB. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls. J Clin Endocrinol Metab. 2004; 89:4338–42.
63. Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab. 2012; 97:1572–80.
64. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. 2007; 92:3483–9.
65. Brito VN, Latronico AC, Cukier P, Teles MG, Silveira LF, Arnhold IJ, et al. Factors determining normal adult height in girls with gonadotropin-dependent precocious puberty treated with depot gonadotropin-releasing hormone analogs. J Clin Endocrinol Metab. 2008; 93:2662–9.
66. Eugster EA. Treatment of central precocious puberty. J Endocr Soc. 2019; 3:965–72.
67. Shim YS, Lim KI, Lee HS, Hwang JS. Long-term outcomes after gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty. PLoS One. 2020; 15:e0243212.
68. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab. 1999; 84:1973–8.
69. Wu V, Zhao V, Issa R, Wilkes M, Wallach E, Rapaport R, et al. Clinical findings influencing time to menarche post gonadotropin-releasing hormone agonist therapy in central precocious puberty. Ann Pediatr Endocrinol Metab. 2021; 26:185–91.
70. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab. 1999; 84:4583–90.
71. Lazar L, Lebenthal Y, Yackobovitch-Gavan M, Shalitin S, de Vries L, Phillip M, et al. Treated and untreated women with idiopathic precocious puberty: BMI evolution, metabolic outcome, and general health between third and fifth decades. J Clin Endocrinol Metab. 2015; 100:1445–51.
72. Martinerie L, de Mouzon J, Blumberg J, di Nicola L, Maisonobe P, Carel JC, et al. Fertility of women treated during childhood with Triptorelin (depot formulation) for central precocious puberty: the PREFER study. Horm Res Paediatr. 2020; 93:529–38.
73. Bertelloni S, Baroncelli GI, Ferdeghini M, Menchini-Fabris F, Saggese G. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropinreleasing hormone analogues. Eur J Pediatr. 2000; 159:369–74.
74. Lazar L, Meyerovitch J, de Vries L, Phillip M, Lebenthal Y. Treated and untreated women with idiopathic precocious puberty: long-term follow-up and reproductive outcome between the third and fifth decades. Clin Endocrinol (Oxf). 2014; 80:570–6.
75. Luo X, Liang Y, Hou L, Wu W, Ying Y, Ye F. Long-term efficacy and safety of gonadotropin-releasing hormone analog treatment in children with idiopathic central precocious puberty: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2021; 94:786–96.
76. Yoon JW, Park HA, Lee J, Kim JH. The influence of gonadotropin-releasing hormone agonists on anthropometric change in girls with central precocious puberty. Korean J Pediatr. 2017; 60:395–402.
77. van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab. 2002; 87:506–12.
78. Park HK, Lee HS, Ko JH, Hwang IT, Lim JS, Hwang JS. The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty. Clin Endocrinol (Oxf). 2012; 77:743–8.
79. Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Tato L. Bone development during GH and GnRH analog treatment. Eur J Endocrinol. 2004; 151 Suppl 1:S47–54.
80. Prentice P, Viner RM. Pubertal timing and adult obesity and cardiometabolic risk in women and men: a systematic review and meta-analysis. Int J Obes (Lond). 2013; 37:1036–43.
Full Text Links
  • APEM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles

Cited

Download

Close

Save citations to file

Download

Close

Email citations

Send Email
recaptcha 영역

Close

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr